CASISD OpenIR
Research Fronts 2019: Clinical Medicine and Biological Sciences
Res Fronts 2019 Collaborators
发表期刊DRUGS OF THE FUTURE
摘要The world of scientific research presents a sprawling, ever-changing landscape. The ability to identify where the action is and, in particular, to track emerging specialty areas, provides a distinct advantage for administrators, policy makers, and others who need to monitor, support, and advance the conduct of research in the face of finite resources. By tracking the world's most significant scientific and scholarly literature and the patterns and groupings of how papers are cited, Research Fronts can be discovered. Following the inaugural report in 2013 by Clarivate Analytics, the company has worked in collaboration with the Chinese Academy of Sciences to publish joint annual reports in which 100 hot Research Fronts are identified. In the latest full report, Research Fronts 2019, a total of 137 Research Fronts are presented, including 100 hot and 37 emerging ones identified by co-citation analysis using the Essential Science Indicators (ESI) database. The Research Fronts are classified into 10 broad research areas in the sciences and social sciences. This article will focus on two research areas: clinical medicine and biological sciences.
2020
卷号45
DOI10.1358/dof.2020.45.4.3151952
语种英语
引用统计
文献类型期刊论文
条目标识符http://ir.casisd.cn/handle/190111/9757
专题中国科学院科技战略咨询研究院
推荐引用方式
GB/T 7714
Res Fronts 2019 Collaborators. Research Fronts 2019: Clinical Medicine and Biological Sciences[J]. DRUGS OF THE FUTURE,2020,45.
APA Res Fronts 2019 Collaborators.(2020).Research Fronts 2019: Clinical Medicine and Biological Sciences.DRUGS OF THE FUTURE,45.
MLA Res Fronts 2019 Collaborators."Research Fronts 2019: Clinical Medicine and Biological Sciences".DRUGS OF THE FUTURE 45(2020).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Res Fronts 2019 Collaborators]的文章
百度学术
百度学术中相似的文章
[Res Fronts 2019 Collaborators]的文章
必应学术
必应学术中相似的文章
[Res Fronts 2019 Collaborators]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。